-- Emergent BioSolutions (EBS) said Tuesday it has signed a $34.5 million deal with Substipharm Biologics to support drug substance manufacturing for the Japanese encephalitis vaccine at its Canton, Massachusetts, facility.
As part of the agreement, Emergent said it will be the exclusive distributor of the vaccine to the US government, following potential US Food and Drug Administration regulatory clearances.
Under a master manufacturing services agreement, Emergent said it will conduct operational and regulatory inspection readiness activities for the vaccine.
Emergent shares were up 1.6% in Tuesday trading.
Price: $8.16, Change: $+0.13, Percent Change: +1.62%